Cell-based therapy uses living cells as the treatment itself. It includes blood stem cell transplants, immune-cell treatments such as CAR-T, and cultured cells used for cartilage repair. Stem cell therapy is one part of this broader field, not another name for all cell-based treatment Stem cell transplantApproved cellular and gene therapy products.
The name alone does not tell you whether a treatment is suitable or approved. That depends on the exact product, disease, patient group, and country.

What Counts as Cell-Based Therapy?
The cells may come from the patient or a donor. Some replace blood-forming cells; others are grown or modified in a laboratory before being given back. The FDA’s combined cellular and gene therapy list includes several kinds of products, including some that do not deliver living cells. Its total should not be read as a count of cell-based treatments Stem cell transplantApproved cellular and gene therapy products.
| Example | What the patient receives | Regulatory context |
|---|---|---|
| Blood stem cell transplant | Blood-forming cells from blood, bone marrow, or cord blood, delivered through a vein | An established procedure for selected blood cancers, blood disorders, and some autoimmune disorders; suitability depends on the diagnosis and transplant type Stem cell transplant |
| Licensed cord blood products, such as HEMACORD and ALLOCORD | Blood-forming cells from donated umbilical cord blood | FDA-listed licensed products with defined indications; not approval for every proposed use of cord blood Approved cellular and gene therapy products |
| CAR-T products, such as KYMRIAH and YESCARTA | A patient’s immune cells modified in a laboratory | FDA-listed products whose approved uses must be checked individually Approved cellular and gene therapy productsCar t cells |
| MACI | A patient’s cultured cartilage cells on a membrane | An FDA-listed cultured-cell product; consult its product-specific label Approved cellular and gene therapy products |
| Ryoncil (remestemcel-L-rknd) | Donor bone-marrow-derived mesenchymal stromal cells (MSCs), at 2 million cells per kilogram per intravenous infusion | FDA-approved on December 18, 2024, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=displayFda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host |
Is It the Same as Stem Cell Therapy?
No. Stem cells can renew themselves and develop into specialized cells, although their capabilities differ by cell type. Blood-forming stem cells, for example, produce blood cells Stem CellStem cell transplant. Stem cell therapy belongs within cell-based therapy, but treatments using mature immune cells or cultured cartilage cells also belong in the broader category Approved cellular and gene therapy products.
Gene therapy overlaps with cell therapy when cells are genetically modified before treatment. The categories are not identical: not every cell treatment involves gene modification, and some gene therapies deliver genetic material without administering living cells Approved cellular and gene therapy productsCar t cells.
What Do the Cells Actually Do?
Replace Blood-Forming Cells
In a blood stem cell transplant, infused cells travel to the bone marrow and restore blood production after intensive treatment. In cancer care, this usually supports recovery from chemotherapy or radiation rather than directly killing the cancer Stem cell transplant.
An autologous transplant uses your own cells; an allogeneic transplant uses a donor’s. The choice depends on the disease, previous treatment, donor availability, and whether you can tolerate preparation. Using your own cells does not make the procedure risk-free; NCI notes a small risk of returning cancer cells with an autologous graft Stem cell transplant. This distinction is central to understanding autologous and allogeneic stem cells.
Act on the Immune System
CAR-T treatment modifies T cells so they recognize a target on cancer cells. After infusion, those cells can attack cells carrying that target Car t cells. Donor blood stem cell transplants can have a different immune effect: donor white blood cells may attack remaining leukemia cells, known as graft-versus-leukemia Stem cell transplant.
Modulate Immune Activity
Ryoncil’s precise mechanism is unclear. Its label describes laboratory findings in which MSCs inhibited T-cell activation, but these findings alone do not establish patient benefit. The label also states that no pharmacokinetic studies have been performed; it does not establish how infused cells distribute or persist in patients FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
What Is Approved and What Is Experimental?
Approval applies to a particular product and its labeled indications, not to cell therapy as a whole. Ryoncil was the first FDA-approved MSC therapy, but its approval for pediatric steroid-refractory acute graft-versus-host disease is not evidence that an MSC infusion treats unrelated conditions Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.
In its single-arm study, 55 patients were enrolled and 54 were treated after a donor blood stem cell transplant. They initially received intravenous Ryoncil twice weekly for four weeks, with additional treatment determined by response. At day 28, 16 treated patients (30%) had a complete response and 22 (41%) had a partial response. Complete response meant resolution in all involved organs; partial response meant improvement without worsening in another organ FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
Among day-28 responders, median response duration was 54 days, measured until progression, new systemic treatment, or death. This was not a survival estimate. The study had no concurrent comparison group, and a response at day 28 is not the same as a cure or proof of benefit for another disease FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
An experimental treatment is still being studied for a particular use. A private clinic’s paid service is not automatically an approved treatment or an authorized clinical trial. FDA warns that a ClinicalTrials.gov entry or a firm’s FDA registration does not establish lawful marketing of an unapproved regenerative product Important patient and consumer information about regenerative medicine therapies.
Japan has separate frameworks for medical provision under the Act on the Safety of Regenerative Medicine and commercialization of regenerative medical products under the Pharmaceuticals and Medical Devices Act. A filed provision plan is not the same as product marketing approval and should not be treated as proof of efficacy 0003Index. This distinction also matters when reading a regenerative medicine overview or comparing clinic services.
What Are the Risks?
The risks differ by treatment. Blood stem cell transplantation and its preparatory treatment can cause infection, mouth sores, nausea, infertility, organ damage, and secondary cancers. With donor transplants, graft-versus-host disease occurs when donor immune cells attack the recipient’s tissues Stem cell transplant.
CAR-T treatment can cause cytokine release syndrome, with high fever and dangerously low blood pressure, as well as serious neurological problems called immune effector cell-associated neurotoxicity syndrome (ICANS). These risks require specialist monitoring and management Car t cells.
In the Ryoncil study, common adverse reactions included infections, fever, bleeding, swelling, abdominal pain, and high blood pressure. Its label warns of hypersensitivity and infusion reactions, infectious-agent transmission, and ectopic tissue formation. Known hypersensitivity to dimethyl sulfoxide or porcine and bovine proteins is a contraindication FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
For unapproved regenerative products, FDA reports concerns including infection, unwanted immune reactions, tumor formation, and cells forming unintended tissue. These warnings should not be presented as a single side-effect profile for every approved cell product Important patient and consumer information about regenerative medicine therapies. The same product-specific approach is needed when asking whether stem cell therapy is safe in Japan.
How Can You Check a Treatment Offer?
- Identify the cells. Ask for the exact product name, cell type, tissue source, dose, and delivery route.
- Match the indication. Compare your diagnosis and age group with the current product label. An approval for one use does not establish approval for another.
- Read the human evidence. Check who was treated, the number of participants, comparison group, measured outcomes, follow-up, and adverse events. A laboratory result or trial registration is not proof of clinical benefit.
- Identify the regulatory pathway. Establish whether the offer is an approved product, an authorized clinical trial, or a private service, and which country’s rules apply.
- Compare with standard care. Discuss the evidence and alternatives with your treating specialist. These document checks also apply when choosing a stem cell hospital in Japan.
A Practical Label Check
Ryoncil illustrates a detail worth checking: its US indication starts at age 2 months in pediatric patients, but the 54 treated study participants were aged 7 months to 17 years. The approved population and the population directly studied are not identical. Reading the indication and clinical-study sections together makes that difference visible; an advertisement saying only “approved cell therapy” would leave it out FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
In short: cell-based therapy is a broad treatment category, not a guarantee of effectiveness. To understand a specific offer, identify the cells, the condition being treated, the supporting human evidence, and its regulatory status.
This article provides general information, not individual medical advice or a personal account of treatment. A qualified clinician should assess whether any option is appropriate for you.
Have questions about treatment in Japan?
Use the contact form to ask what documentation is needed for an initial inquiry. Treatment suitability requires a clinician’s assessment.




